Author

P. Botwina

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:benchmarking· 1 Organism:mouse· 1 Organism:virus· 1

Frequent Co-Authors

K. Pyrc· 3 shared A. Dabrowska· 2 shared A. Szczepanski· 2 shared A. Arenas-Pinto· 1 shared A. Czarna· 1 shared A. G. Schatzlein· 1 shared A. Matsuda· 1 shared A. Milewska· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

K. Pyrc

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2.

A. Dabrowska, A. Szczepanski, P. Botwina, N. Mazur-Panasiuk, H. Jirincova, L. Rabalski, T. Zajic, G. Popowicz, K. Pyrc

This study evaluates the efficacy of antivirals against SARS-CoV-2 variants, including Omicron, Delta, and the early 2020 isolate.

bioRxiv · Dec 21, 2021 · PreprintMicrobiology

Acriflavine, a clinically aproved drug, inhibits SARS-CoV-2 and other betacoronaviruses

V. Napolitano, A. Dabrowska, K. Schorpp, A. Mourao, E. Barreto-Duran, M. Benedyk, P. Botwina, S. Brandner, M. Bostock, Y. Chykunova, A. Czarna, G. Dubin, T. Frohlich, M. Hoelscher, M. Jedrysik, , K. Pyrc

This study identifies acriflavine as a potent inhibitor of SARS-CoV-2 and other betacoronaviruses, effective in cellular models, in vivo, and ex vivo.

bioRxiv · Mar 20, 2021Microbiology

SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray

K. Pyrc, A. Milewska, E. B. Duran, P. Botwina, R. Lopes, A. Arenas-Pinto, M. Badr, R. Mellor, T. Kalber, D. Fernandez-Reyes, A. G. Schatzlein, I. F. Uchegbu

This paper demonstrates that GCPQ, a mucoadhesive chitosan derivative, reduces SARS-CoV-2 infectivity in cell cultures and shows promising nasal retention in mice, supporting its potential as a nasal spray for COVID-19 prevention.

bioRxiv · Dec 10, 2020 · PreprintPharmacology & Toxicology